“…These compounds were evaluated against 60 human cell lines derived from seven clinically isolated cancer types (lung, colon, melanoma, renal, ovarian, brain and leukemia) according to a standard protocol (conducted at the National Cancer Institute, Bethesda, MD, USA) with the sulforhodamine B (SRB) assay [21][22][23][24]. The evaluated compounds 1 y 2 showed antitumor activity for the leukemia cells lines CCRF-CEM, K-562, MOLT-4 and RPMI 8226; for non-small cell lung cancer HOP-92, NCI-H23; colon cancer HCC-2998, HCT-15, SW-620; melanoma LOX IMVI cell line, IGROV1 ovarian cancer and renal cancer A486 and ACHN.…”